{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-045601","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.509891+00:00","generated_at":"2026-06-24T01:52:34.961600+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protara Therapeutics Q2 2022 net loss $8.5M ($0.80/share); cash $112.8M","bullets":["Net loss of $8.5M ($0.80 per share) vs $12.8M ($1.14) in Q2 2021.","Cash, cash equivalents and marketable debt securities of $112.8M as of June 30, 2022.","R&D expenses decreased to $3.1M from $5.9M; G&A decreased to $5.6M from $6.9M.","ADVANCED-1 Phase 1 trial of TARA-002 in NMIBC enrollment progressing; Trials in Progress poster presented at ASCO June 2022.","EMA granted orphan drug designation to TARA-002 for lymphatic malformations; Phase 2 trial planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-045601","json":"https://secwatch.observer/filing/0001213900-22-045601.json","markdown":"https://secwatch.observer/filing/0001213900-22-045601.md","text":"https://secwatch.observer/filing/0001213900-22-045601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/0001213900-22-045601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/ea163937-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:52:34.961600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}